Erratum: Synthesis and SAR of 5,6-diarylpyridines as human CB1 inverse agonists (Bioorganic and Medicinal Chemistry Letters (2005) 15 (645) DOI: 10.1016/j.bmcl.2004.11.031);Synthesis and SAR of 5,6-diarylpyridines as human CB1 inverse agonists

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 3, 2005, Pages 645-651

  Meurer, Laura C ^a   Finke, Paul E ^a   Mills, Sander G ^a   Walsh, Thomas F ^a   Toupence, Richard B ^a   Goulet, Mark T ^a   Wang, Junying ^a   Tong, Xinchun ^a   Fong, Tung M ^a   Lao, Julie ^a   Schaeffer, Marie Therese ^a   Chen, Jing ^a   Shen, Chun Pyn ^a   Sloan Stribling, D ^a   Shearman, Lauren P ^a   Strack, Alison M ^a   Van Der Ploeg, Lex H T ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Human CB1 receptor; Inverse agonist; Pyridine

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; FUNCTIONAL GROUP; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SYNTHESIS; MALE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

EID: 19944432440     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.01.055     Document Type: Erratum

References (28)

1. For general reviews of cannabinoid receptor ligands and potential therapeutic applications, see: G. Di Carlo, and A.A. Izzo Expert Opin. Invest. Drugs 12 2003 39
2. R.G. Pertwee Expert Opin. Invest. Drugs 9 2000 1553
3. J.-N. Xiang, and J.C. Lee Ann. Rep. Med. Chem. 34 1999 199
4. C.R. Trillou, C. Delgorge, C. Menet, M. Arnone, and P. Soubrie Int. J. Obesity 28 2004 640
5. A. Zimmer, A.M. Zimmer, A.G. Hohmann, M. Herkenham, and T.I. Bonner Proc. Natl. Acad. Sci. U.S.A. 96 1999 5780
6. F. Barth, and M. Rinaldi-Carmona Curr. Med. Chem. 6 1999 745
7. M. Rinaldi-Carmona, F. Barth, M. Heaulme, D. Shire, B. Calandra, C. Congy, S. Martinez, J. Maruani, G. Neliat, D. Caput, P. Ferrarra, P. Soubrie, J.C. Breliere, and G. Le Fur FEBS Lett. 350 1994 240
8. G. Colombo, R. Agabio, G. Diaz, C. Lobina, R. Reali, and G.L. Gessa Life Sci. 8 1998 113
9. C.R. Trillou, C. Arnone, N. Gonalons, P. Keane, J.P. Maffrand, and P. Soubrie J. Physiol. Regul. Integr. Comp. Physiol. 284 2003 345
10. D. Cota, G. Marsicano, M. Tschop, Y. Grubler, C. Flachskamm, M. Schubert, D. Auer, A. Yassouridis, C. Thone-Reineke, S. Ortmann, F. Tomassoni, C. Cervino, E. Nisoli, A.C.E. Linthorst, R. Pasquali, B. Lutz, G.K. Stalla, and U. Pagotto J. Clin. Invest. 112 2003 423
11. R.G. Pertwee Pharmacol. Ther. 74 1997 129
12. B.K. Koe, G.M. Milne, A. Weissman, M.R. Johnson, and L.S. Melvin Eur. J. Pharmacol. 109 1985 201
13. T.E. D'Ambra, K.G. Estep, M.R. Bell, M.R. Eissenstat, K.A. Josef, S.J. Ward, D.A. Haycock, E.R. Baizman, F.M. Casiano, and N.C. Beglin J. Med. Chem. 35 1992 124
14. S. Mato, A. Pazos, and E.M. Valdizan Eur. J. Pharmacol. 443 2002 43
15. R.S. Landsman, T.H. Burkey, P. Consroe, W.R. Roeske, and H.I. Yamamura Eur. J. Pharmacol. 1997 334R1 334R2
16. M. Bouaboula, S. Perrachon, L. Milligan, X. Canat, M. Rinaldi-Carmona, M. Portier, F. Barth, B. Calandra, F. Pecceu, J. Lupker, J.P. Maffrand, G. Le Fur, and P. Casellas J. Biol. Chem. 272 1997 22330
17. R. Lan, Q. Liu, P. Fan, S. Lin, S.R. Fernando, D. McCallion, R. Pertwee, and A. Makriyannis J. Med. Chem. 42 1999 769
18. J.L. Wiley, R.G. Jefferson, M.C. Grier, A. Mahadevan, R.K. Razdan, and B.R. Martin J. Pharm. Exp. Ther. 296 2001 1013
19. J.-Y. Shim, W.J. Welsh, E. Cartier, J.L. Edwards, and A.C. Howlett J. Med. Chem. 45 2002 1447
20. The reported binding results (±SEM) were an average of 2-4 independent determinations, which were normally within 50% of the average value based on a standard sample. For the assay conditions for both the binding and functional assays, see: C.C. Felder, K.E. Joyce, E.M. Briley, J. Mansouri, K. Mackie, O. Blond, Y. Lai, A.L. Ma, and R.L. Mitchell Mol. Pharmacol. 48 1995 443
21. 1H NMR and/or LC-MS data were in agreement with the assigned structures. For full experimental and spectral details, see: Finke, P. E.; Meurer, L. C.; Debenham, J. S.; Toupence, R. B.; Walsh, T. F. WO Patent 03/082191 A2, 2003; Chem. Abstr. 2003, 139, 307686f
22. M.S. Newman, and D.F. Reid J. Org. Chem. 23 1958 665
23. An EPO patent from Sanofi-Synthelabo related to this same 2-amido pyridine structure has recently been published, see: Barth, F.; Martinez, S.; Rinaldi-Carmona, M. WO Patent 03/084930 A1, 2003; Chem. Abstr. 2003, 139, 307689j
24. K. Ishizumi, K. Koga, and S. Yamada Chem. Pharm. Bull. 16 1968 492
25. J.P. Boukou-Poba, M. Farnier, and R. Guilard Tetrahedron Lett. 19 1979 1717
26. J. Barluenga, M. Ferrero, and F. Palacios J. Chem. Soc., Perkin Trans. 1 1990 2193
27. 50 ratios were observed for the more active benzyloxy compounds of Tables 1 and 2 (50-500) than for the less active amides of Table 3 (0.2-10) and Table 4 (5-30)
28. W.A. Ritschel, and G.L. Kearns J.I. Graubart Handbook of Basic Pharmacokinetics Including Clinical Applications 5th ed. 1999 American Pharmaceutical Association